FOXO4-DRI, 10mg

FOXO4-DRI Description

FOXO4-DRI is an experimental peptide that has been investigated for its ability to selectively target senescent cells—cells that have stopped dividing but remain metabolically active. Research has focused on the interaction between FOXO4 and p53, a pathway involved in the survival of senescent cells. Disrupting this interaction has been studied as a method of promoting apoptosis in certain senescent cell populations.

Current FOXO4-DRI research remains primarily preclinical, with studies examining its effects in cellular and animal models of aging, fibrosis, cancer biology, and tissue regeneration.

Pulmonary Fibrosis Research

Researchers have also examined FOXO4-DRI in experimental models of pulmonary fibrosis, a condition characterized by abnormal accumulation of fibrotic tissue within the lungs.

In preclinical studies, FOXO4-DRI was associated with reductions in senescent cell populations and decreased expression of factors associated with the senescence-associated secretory phenotype (SASP). Researchers also observed changes in fibrosis-related tissue morphology and collagen deposition.

These findings have contributed to broader research into the relationship between cellular senescence, SASP signaling, and fibrotic tissue remodeling.

Age-Related Cellular Changes

FOXO4-DRI has been investigated in aged animal models to better understand the role of cellular senescence in age-associated physiological changes.

One area of research has focused on senescent Leydig cells, which are involved in testosterone production within the testes. In aged mice, researchers examined whether selective removal of these cells could alter the surrounding cellular environment and age-associated changes in Leydig cell function.

These findings provide a model for studying how senescent-cell clearance may influence tissue function during aging.

Cartilage Research

FOXO4-DRI has also been evaluated in laboratory studies involving human chondrocytes, the cells responsible for producing and maintaining cartilage tissue.

In vitro research has examined whether FOXO4-DRI can selectively reduce senescent cell populations within expanded chondrocyte cultures. While reductions in markers of cellular senescence have been observed, the extent to which senescent-cell clearance affects chondrogenic potential and cartilage formation remains under investigation.

This research highlights FOXO4-DRI as an experimental tool for studying cellular senescence and its relationship with cartilage biology and tissue regeneration.

Research Status: FOXO4-DRI remains an investigational research compound. Current evidence is primarily derived from laboratory and animal studies, and its biological effects, safety profile, and clinical relevance in humans have not been established.

FOXO4-DRI is not approved by the U.S. Food and Drug Administration for human use. Its safety, efficacy, and pharmacological profile have not been established in approved FDA clinical trials. This compound is intended strictly for laboratory research purposes and is not for human or veterinary use.